 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
From the company's web site (http://www.polymedix.com) PolyMedix is developing novel, first in class therapies for serious, life threatening, acute disorders. Using our proprietary computational drug design technology, we have created our two lead product candidates which have completed Phase 1B clinical trials. PMX-60056 is a synthetic, small-molecule designed as an anticoagulant reversing agent and PMX-30063 is an antibiotic that mimics natural host defense proteins. Phase 2 studies for both of these products are planned to commence during 2010. PolyMedix’s approach to developing high-value therapeutic drugs is with biomimetics - novel small molecule compounds and polymers which mimic the activity of proteins. These compounds are designed with a proprietary computational technology platform which focuses on a specific field of biology with many potential product opportunities: membrane:protein and protein:protein interactions. First two compounds in clinical trials PMX-30063 Antibiotic Using a proprietary computational drug design technology, created by National Academy of Science members Drs. William DeGrado and Michael Klein and licensed from the University of Pennsylvania, PolyMedix has developed a completely novel class of antibiotic drugs: small synthetic molecules that mimic the activity of host defense proteins and imitate natural human immunity. With a completely different mechanism of action from other antibiotics, these unique compounds function in a way which makes bacterial resistance unlikely to develop. The first compound in this series and in clinical testing is PMX-30063, which is being developed for the broad treatment of Staphylococcus (MRSA) infections. Phase 1 clinical results showed that it was possible to safely administer PMX-30063 without any serious side effects at single or multiple doses which exceeded those associated with full efficacy in animal models of infection. In addition, bactericidal activity has been achieved in human blood. PMX-60056 Heparin reversal In all subjects receiving PMX-60056, there was a rapid and complete reversal of the anticoagulant action of heparin, as measured by ACT and aPTT. Each subject’s minimum ACT and aPTT readings after being dosed with PMX-60056 were at or below the subject’s ACT and aPTT readings prior to being dosed with heparin. The heparin reversal appeared to occur at or before the end of the 10-minute infusion of PMX-60056, suggesting that the 0.3 mg/kg dose may have been in excess of requirements for 70U/kg heparin. Furthermore, the reversal was permanent: there was no return of anticoagulation during the hours required for heparin’s effects to decline naturally. I first learned of the company from a post by Biomaven Message 26093658 Message 26431043 and later found some by Catfish Message 25784159 Message 25814715 Message 25895872 Message 25975821 and by Rick Message 26093873 The trading symbol is PYMX. Jason | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |